Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine in Healthy Adults
NCT05231369Phase 1Unknown
- Sponsor
- Chulalongkorn University
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChulaCov19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chulalongkorn University. Primary endpoints: Frequency of solicited local reactogenicity adverse events at Day 29, Frequency of solicited systemic reactogenicity adverse events at Day 29 and 2 more. Status: unknown.
02
Drugs
ChulaCov19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05231369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231369.